Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation

Ali Salim, Matthew Martin, Carlos Brown, Kenji Inaba, Bradley Roth, Pantelis Hadjizacharia, Angela Mascarenhas, Peter Rhee, Demetrios Demetriades

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The aggressive management of brain-dead (cadaveric) organ donors has been shown to increase organs available for transplantation. Some centers use hormone therapy with thyroid hormone (T4) in selected donors. The purpose of this study is to evaluate the effects of T4 on organs available for transplantation. A policy of aggressive donor management was adopted at our trauma center in 1998. T4 therapy is reserved for the hemodynamically unstable donors who require significant vasopressor support. The records of patients who successfully donated organs between January 2001 and December 2005 were reviewed. Organ donor demographics and whether T4 was used was examined for each donor. T4 was used in 96 of 123 donors (78%). Compared with donors who did not receive T4, those that did were similar in age (32 ± 14 vs. 38 ± 21, p = 0.148), had more organs donated (3.9 ± 1.7 vs. 3.2 ± 1.7, p = 0.048), and had no differences in brain-death related complications. Despite the severe hemodynamic instability in the T4 group, the number of organs harvested from this group was significantly more than in patients who did not receive T4. The use of T4 in this group may result in the increased salvage of transplantable organs.

Original languageEnglish (US)
Pages (from-to)405-409
Number of pages5
JournalClinical Transplantation
Volume21
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

Brain Death
Organ Transplantation
Thyroid Hormones
Tissue Donors
Trauma Centers
Thyroxine
Hemodynamics
Demography
Hormones
Therapeutics

Keywords

  • Brain death
  • Organdonor
  • Thyroid hormone
  • Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Salim, A., Martin, M., Brown, C., Inaba, K., Roth, B., Hadjizacharia, P., ... Demetriades, D. (2007). Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. Clinical Transplantation, 21(3), 405-409. https://doi.org/10.1111/j.1399-0012.2007.00659.x

Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. / Salim, Ali; Martin, Matthew; Brown, Carlos; Inaba, Kenji; Roth, Bradley; Hadjizacharia, Pantelis; Mascarenhas, Angela; Rhee, Peter; Demetriades, Demetrios.

In: Clinical Transplantation, Vol. 21, No. 3, 05.2007, p. 405-409.

Research output: Contribution to journalArticle

Salim, A, Martin, M, Brown, C, Inaba, K, Roth, B, Hadjizacharia, P, Mascarenhas, A, Rhee, P & Demetriades, D 2007, 'Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation', Clinical Transplantation, vol. 21, no. 3, pp. 405-409. https://doi.org/10.1111/j.1399-0012.2007.00659.x
Salim, Ali ; Martin, Matthew ; Brown, Carlos ; Inaba, Kenji ; Roth, Bradley ; Hadjizacharia, Pantelis ; Mascarenhas, Angela ; Rhee, Peter ; Demetriades, Demetrios. / Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. In: Clinical Transplantation. 2007 ; Vol. 21, No. 3. pp. 405-409.
@article{cb254afc40a04ec2841a7e2b566686d6,
title = "Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation",
abstract = "The aggressive management of brain-dead (cadaveric) organ donors has been shown to increase organs available for transplantation. Some centers use hormone therapy with thyroid hormone (T4) in selected donors. The purpose of this study is to evaluate the effects of T4 on organs available for transplantation. A policy of aggressive donor management was adopted at our trauma center in 1998. T4 therapy is reserved for the hemodynamically unstable donors who require significant vasopressor support. The records of patients who successfully donated organs between January 2001 and December 2005 were reviewed. Organ donor demographics and whether T4 was used was examined for each donor. T4 was used in 96 of 123 donors (78{\%}). Compared with donors who did not receive T4, those that did were similar in age (32 ± 14 vs. 38 ± 21, p = 0.148), had more organs donated (3.9 ± 1.7 vs. 3.2 ± 1.7, p = 0.048), and had no differences in brain-death related complications. Despite the severe hemodynamic instability in the T4 group, the number of organs harvested from this group was significantly more than in patients who did not receive T4. The use of T4 in this group may result in the increased salvage of transplantable organs.",
keywords = "Brain death, Organdonor, Thyroid hormone, Transplantation",
author = "Ali Salim and Matthew Martin and Carlos Brown and Kenji Inaba and Bradley Roth and Pantelis Hadjizacharia and Angela Mascarenhas and Peter Rhee and Demetrios Demetriades",
year = "2007",
month = "5",
doi = "10.1111/j.1399-0012.2007.00659.x",
language = "English (US)",
volume = "21",
pages = "405--409",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation

AU - Salim, Ali

AU - Martin, Matthew

AU - Brown, Carlos

AU - Inaba, Kenji

AU - Roth, Bradley

AU - Hadjizacharia, Pantelis

AU - Mascarenhas, Angela

AU - Rhee, Peter

AU - Demetriades, Demetrios

PY - 2007/5

Y1 - 2007/5

N2 - The aggressive management of brain-dead (cadaveric) organ donors has been shown to increase organs available for transplantation. Some centers use hormone therapy with thyroid hormone (T4) in selected donors. The purpose of this study is to evaluate the effects of T4 on organs available for transplantation. A policy of aggressive donor management was adopted at our trauma center in 1998. T4 therapy is reserved for the hemodynamically unstable donors who require significant vasopressor support. The records of patients who successfully donated organs between January 2001 and December 2005 were reviewed. Organ donor demographics and whether T4 was used was examined for each donor. T4 was used in 96 of 123 donors (78%). Compared with donors who did not receive T4, those that did were similar in age (32 ± 14 vs. 38 ± 21, p = 0.148), had more organs donated (3.9 ± 1.7 vs. 3.2 ± 1.7, p = 0.048), and had no differences in brain-death related complications. Despite the severe hemodynamic instability in the T4 group, the number of organs harvested from this group was significantly more than in patients who did not receive T4. The use of T4 in this group may result in the increased salvage of transplantable organs.

AB - The aggressive management of brain-dead (cadaveric) organ donors has been shown to increase organs available for transplantation. Some centers use hormone therapy with thyroid hormone (T4) in selected donors. The purpose of this study is to evaluate the effects of T4 on organs available for transplantation. A policy of aggressive donor management was adopted at our trauma center in 1998. T4 therapy is reserved for the hemodynamically unstable donors who require significant vasopressor support. The records of patients who successfully donated organs between January 2001 and December 2005 were reviewed. Organ donor demographics and whether T4 was used was examined for each donor. T4 was used in 96 of 123 donors (78%). Compared with donors who did not receive T4, those that did were similar in age (32 ± 14 vs. 38 ± 21, p = 0.148), had more organs donated (3.9 ± 1.7 vs. 3.2 ± 1.7, p = 0.048), and had no differences in brain-death related complications. Despite the severe hemodynamic instability in the T4 group, the number of organs harvested from this group was significantly more than in patients who did not receive T4. The use of T4 in this group may result in the increased salvage of transplantable organs.

KW - Brain death

KW - Organdonor

KW - Thyroid hormone

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=34248177897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248177897&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2007.00659.x

DO - 10.1111/j.1399-0012.2007.00659.x

M3 - Article

C2 - 17488392

AN - SCOPUS:34248177897

VL - 21

SP - 405

EP - 409

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

ER -